Virios Therapeutics, Inc.: insider trades · United States · SEC (Form 4)

About Virios Therapeutics, Inc.

Virios Therapeutics, Inc. is a U.S.-listed biopharmaceutical company that trades on the NASDAQ market in the United States. A key point for investors is that the company changed its corporate name in late 2024 to Dogwood Therapeutics, Inc.; the most recent SEC filings reflect that legal and strategic transition. The company was originally formed in Delaware in 2020, with operational roots in Georgia, and its principal executive office had been located in Alpharetta, Georgia. From the outset, the business was built around developing antiviral-based therapies for disorders believed to involve an abnormal immune response triggered by viral infection. Virios’ core scientific focus has been on clinical-stage programs targeting fibromyalgia, Long COVID, and related pain-and-fatigue syndromes. Its lead asset, IMC-1, is a fixed-dose combination of famciclovir and celecoxib designed to address both a potential viral driver and the inflammatory component of disease. The company has also referenced follow-on programs, including IMC-2 for Long COVID, and after the 2024 transaction it broadened its development footprint through the addition of other clinical assets. That profile is typical of a small-cap biotechnology company: a concentrated pipeline, heavy dependence on clinical milestones, and value creation tied primarily to trial readouts and regulatory progress rather than near-term commercial sales. From a competitive standpoint, Virios/Dogwood operates in highly contested therapeutic niches where it competes with other biotech developers and specialty pharmaceutical groups focused on chronic pain, immune-mediated disease, and post-viral syndromes. It does not yet have a mature commercial franchise comparable to large-cap pharma peers; instead, its investment case is driven by the differentiated nature of its product candidates and the possibility of advancing them into later-stage development. For investors, that means the stock should be viewed as a high-risk, event-driven biotech story, with sensitivity to funding needs, dilution risk, and trial outcomes. Geographically, the company remains primarily U.S.-based, with its historic corporate center in Georgia and its listing in the United States on NASDAQ. Its footprint is still largely research and development oriented, rather than commercial, so its geographic presence is limited compared with multinational pharmaceutical groups. Recent notable developments include alignment with the FDA on the Phase 3 development plan for IMC-1 in fibromyalgia, and the October 2024 corporate reorganization that transformed Virios into Dogwood Therapeutics and expanded the clinical asset base. For French-speaking investors, this is best understood as a speculative U.S. biotech name whose share price is likely to be driven by clinical data, financing actions, and regulatory announcements.